Exelixis (EXEL) Competitors

Halozyme Therapeutics (NASDAQ:HALO) and Exelixis (NASDAQ:EXEL) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking, profitability, risk and earnings.

Does the media refer more to HALO or EXEL?

In the previous week, Exelixis had 2 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 6 mentions for Exelixis and 4 mentions for Halozyme Therapeutics. Exelixis' average media sentiment score of 1.01 beat Halozyme Therapeutics' score of 0.34 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exelixis	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in HALO or EXEL?

Exelixis received 75 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. However, 68.99% of users gave Halozyme Therapeutics an outperform vote while only 68.62% of users gave Exelixis an outperform vote.

Company	Underperform	Outperform
Halozyme Therapeutics	Outperform Votes 476 68.99%	Underperform Votes 214 31.01%
Exelixis	Outperform Votes 551 68.62%	Underperform Votes 252 31.38%

Which has better earnings and valuation, HALO or EXEL?

Halozyme Therapeutics has higher earnings, but lower revenue than Exelixis. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$660.12 million	6.76	$202.13 million	$1.31	25.88
Exelixis	$1.61 billion	3.88	$182.28 million	$0.48	40.00

Is HALO or EXEL more profitable?

Halozyme Therapeutics has a net margin of 25.76% compared to Exelixis' net margin of 9.24%. Halozyme Therapeutics' return on equity of 184.32% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	25.76%	184.32%	16.05%
Exelixis	9.24%	6.20%	5.10%

Which has more volatility & risk, HALO or EXEL?

Halozyme Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Do insiders and institutionals believe in HALO or EXEL?

96.3% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 84.7% of Exelixis shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 2.9% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Do analysts rate HALO or EXEL?

Halozyme Therapeutics presently has a consensus price target of $54.78, suggesting a potential upside of 60.97%. Exelixis has a consensus price target of $25.33, suggesting a potential upside of 31.67%. Given Halozyme Therapeutics' higher probable upside, research analysts clearly believe Halozyme Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Exelixis	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

Halozyme Therapeutics beats Exelixis on 10 of the 17 factors compared between the two stocks.